Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Conditions

• Corona Virus Disease 2019 (COVID-19)

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Tocilizumab — DRUG
  Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Study Details

IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Key Dates

Start date

Jul 23, 2020

Status verified

Dec 2020

Primary completion

Dec 10, 2020

Completion

Dec 10, 2020

Study Design

Enrollment

200 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Arms

• No Intervention: Control
• Experimental: Tocilizumab
• Experimental: Remdesivir
• Active Comparator: Standard Treatment

Primary Outcome Measure

Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen [ Time Frame: 7 days ]